Company Overview and News

36
5 Russell 3000 Top Dogs Exceed 15% Target Net Gains To June 2019

2018-06-11 seekingalpha
"All Russell US Indexes are subsets of the Russell 3000 Index, [namely] large-cap Russell 1000 & small-cap Russell 2000 Indexes. These Indexes are. building blocks of financial-products [and] performance-benchmarks."---ftserussell.com.
ANH.PRA GMRE.PRA ANH.PRC CHMI.PRA ANH.PRB ANH NYMTO ORC STWD.WI CHMI NYMTP GMRE CYS.PRA CYS.PRB TWO TWO.PRA TWO.PRB TWO.PRC AJXA PEGI NRZ DX NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE CYS NLY.PRC NLY.PRF NLY.PRG PEG DX.PRB NYMT DX.PRA STWD AJX

65
Top 51 Real Estate WallStars Flaunt Yields To 12.2% And Target Gains To 111.3% By May 2019

2018-05-29 seekingalpha
IRSA Propiedades led by net gains, while Two Harbors led by yield. Top ten gainers, GLPI, AJX, BPY, RESI, HASI, APTS, LMRK, CLNS, IRS, & IRCP gains ranged 17.8%-111.3% 5/25/18.
ANH.PRA SLDA ANH.PRC LMRK ANH.PRB ANH ABRN CIM TWO TWO.PRA TWO.PRB TWO.PRC AJXA CIM.PRA ABR CLNS IVR.PRA NRZ IVR.PRB CLNS.PRJ CLNS.PRI IVR.PRC CLNS.PRH DX GLPI CLNS.PRG CLNS.PRE CLNS.PRD CIM.PRB CLNS.PRB ARR ABRN.CL IVR DX.PRB ARR.PRB DX.PRA ARR.PRA AJX ABR.PRB ABR.PRC ABR.PRA

46
50 Russell 3000 Stocks Yield 7.34% To 14.96% For May

2018-05-08 seekingalpha
"All Russell US Indexes are subsets of the Russell 3000 Index, [namely] large-cap Russell 1000 & small-cap Russell 2000 Indexes. These Indexes are. building blocks of financial-products [and] performance-benchmarks."---ftserussell.com.
GMRE.PRA SLDA CHMI.PRA NYMTO ORC STWD.WI CHMI NYMTP GMRE CYS.PRA CYS.PRB TWO AGNC TWO.PRA TWO.PRB TWO.PRC AJXA PEGI NRZ NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE CYS NLY.PRC NLY.PRF NLY.PRG SIR GNL PEG NYMT STWD AJX GNL.PRA

6
Great Ajax's (AJX) CEO Larry Mendelsohn on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good afternoon and welcome to the Great Ajax Corporation's First Quarter 2018 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note, this event is being recorded.
AJX FNMA AJXA

4
Great Ajax Corp 2018 Q1 - Results - Earnings Call Slides

2018-05-01 seekingalpha
The following slide deck was published by Great Ajax Corp in conjunction with their 2018 Q1 earnings call.
AJX AJXA

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 38983D409